Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aseptic processing contamination case studies and the pharmaceutical quality system.

Richard L Friedman1

  • 1Food & Drug Administration, Center for Drug Evaluation & Research, Division of Manufacturing & Product Quality, USA.

PDA Journal of Pharmaceutical Science and Technology
|June 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Flp type IV pilus operon of <i>Mycobacterium tuberculosis</i> is expressed upon interaction with macrophages and alveolar epithelial cells.

Frontiers in cellular and infection microbiology·2022
Same author

Dosage unit uniformity and dissolution testing of extended-release pharmaceutical products marketed in the U.S.

International journal of pharmaceutics·2022
Same author

Quality Testing of Difficult-to-Make Prescription Pharmaceutical Products Marketed in the US.

JAMA network open·2020
Same author

Microbial Risk in Pharmaceutical Manufacturing and ICH Q9.

PDA journal of pharmaceutical science and technology·2013
Same author

Author response.

PDA journal of pharmaceutical science and technology·2012
Same author

Burkholderia cepacia: This Decision Is Overdue.

PDA journal of pharmaceutical science and technology·2012
Same journal

A PAT-aligned framework for installing and operating particle counting systems to detect pre-limit particle-size distribution shifts in ISO-8 (non-sterile) controlled areas.

PDA journal of pharmaceutical science and technology·2026
Same journal

Using Positive Controls to Define the Defect Detection Range for CCIT Method Development and Validation.

PDA journal of pharmaceutical science and technology·2026
Same journal

Patient-Centric Drug Delivery: Establishing Injection Hold Time Limits for Large Volume Autoinjectors.

PDA journal of pharmaceutical science and technology·2026
Same journal

Gas flow through micro-capillaries â which flow law is most suitable to predict the flow rate through micro-capillaries?

PDA journal of pharmaceutical science and technology·2026
Same journal

Peer Review.

PDA journal of pharmaceutical science and technology·2026
Same journal

In-situ Verification of Disinfection Rotation for Contamination Control.

PDA journal of pharmaceutical science and technology·2026
See all related articles

Reviewing parenteral drug contamination cases from 2000-2004 highlights Current Good Manufacturing Practice (CGMP) deficiencies. A robust quality system is essential for preventing drug contamination events.

Area of Science:

  • Pharmaceutical Science
  • Quality Assurance
  • Regulatory Affairs

Background:

  • Parenteral drug contamination poses significant risks to patient safety.
  • Analysis of historical contamination events is crucial for improving manufacturing practices.

Purpose of the Study:

  • To review case studies of parenteral drug contamination between 2000-2004.
  • To identify common Current Good Manufacturing Practice (CGMP) deficiencies linked to these events.
  • To underscore the importance of quality systems in preventing contamination.

Main Methods:

  • Case study analysis of parenteral drug contamination events.
  • Review of industry conference presentations and FDA advisory committee meeting data (2000-2004).
  • Identification and discussion of associated CGMP deficiencies.

Related Experiment Videos

Main Results:

  • Multiple parenteral drug contamination events occurred between 2000-2004.
  • Specific CGMP deficiencies were consistently associated with these contamination incidents.
  • Failures in quality systems were a recurring theme in contamination cases.

Conclusions:

  • Addressing identified CGMP deficiencies is critical for parenteral drug safety.
  • A well-implemented and functioning quality system is paramount for effective contamination prevention.
  • Continuous improvement of manufacturing processes and quality oversight is necessary to mitigate risks.